We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
News

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
News

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH has announced that it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV ("Janssen") triggering an undisclosed payment to Proteros.

Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic areas. The objective of this oncology focused project was for Proteros to discover potent and selective small molecule inhibitor series against a novel protein target.

Based on the establishment of a de novo X-ray crystallography system, HTS screening and biophysical assay technology of the novel target Proteros delivered multiple chemical series meeting stringent compound criteria.

Dr. Peter Reinemer, Chief Operating Officer for Proteros, stated: "We are very pleased to be Janssen's partner in one of their oncology discovery programs and that we have been able to deliver new compound classes for a challenging novel drug target."

Advertisement